Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 6/20 | 0.60 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.60 |
| ▸ | SCD | O00767 | 7/20 | 0.44 |
| ▸ | SCD5 | Q86SK9 | 7/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ITK | Q08881 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1166335 | 0.92 | HCRTR2 (0.58) | HCRTR2HCRTR1SCDSCD5SMN1; SMN2 | |
| SCHEMBL1166907 | 0.92 | HCRTR2 (0.59) | HCRTR2HCRTR1SCDSCD5SMN1; SMN2 | |
| SCHEMBL1166674 | 0.91 | HCRTR2 (0.58) | HCRTR2HCRTR1SCDSCD5SMN1; SMN2 | |
| SCHEMBL1166508 | 0.90 | HCRTR2 (0.59) | HCRTR2HCRTR1SCDSCD5SMN1; SMN2 | |
| SCHEMBL1166992 | 0.89 | HCRTR2 (0.64) | HCRTR2HCRTR1SCDSCD5SMN1; SMN2 | |
| SCHEMBL1166600 | 0.87 | HCRTR2 (0.59) | HCRTR2HCRTR1SCDSCD5SMN1; SMN2 | |
| SCHEMBL1166994 | 0.86 | HCRTR2 (0.53) | HCRTR2HCRTR1SCDSCD5SMN1; SMN2 | |
| SCHEMBL1167232 | 0.85 | HCRTR2 (0.58) | HCRTR2HCRTR1SCDSCD5SMN1; SMN2 | |
| SCHEMBL1167020 | 0.84 | HCRTR2 (0.82) | HCRTR2HCRTR1 | |
| SCHEMBL1166400 | 0.84 | HCRTR2 (0.67) | HCRTR2HCRTR1SCDSCD5SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034516-A1 | AMINOPYRAZOLE DERIVATIVES | ACTELION (CH) | 2011-02-10 | — | — | US | claimed |
| US-20110034516-A1 | AMINOPYRAZOLE DERIVATIVES | ACTELION (CH) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034516-A1 | AMINOPYRAZOLE DERIVATIVES | CYP3A43, CYP1A2, CYP3A5 | HCRTR2 2700/4885HCRTR1 2862/4885SCD 4685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.